CytoDyn Inc.
CYDY
$0.3172
$0.00722.32%
OTC PK
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -32.89% | -19.67% | -9.68% | -27.85% | -36.87% |
| Depreciation & Amortization | -- | -131.43% | -122.50% | -105.81% | -100.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.14% | 11.10% | 3.77% | -54.92% | -55.50% |
| Operating Income | 15.14% | -11.10% | -3.77% | 54.92% | 55.50% |
| Income Before Tax | 107.51% | 86.29% | 73.35% | 72.95% | 37.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 107.51% | 86.29% | 73.35% | 72.95% | 37.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 107.51% | 86.29% | 73.35% | 72.95% | 37.56% |
| EBIT | 15.14% | -11.10% | -3.77% | 54.92% | 55.50% |
| EBITDA | 15.10% | -11.24% | -3.91% | 54.87% | 55.37% |
| EPS Basic | 105.88% | 84.63% | 72.22% | 72.77% | 49.67% |
| Normalized Basic EPS | 44.79% | 47.37% | 48.62% | 62.86% | 65.90% |
| EPS Diluted | 99.81% | 83.57% | 72.54% | 72.99% | 51.02% |
| Normalized Diluted EPS | 45.31% | 47.77% | 48.97% | 63.09% | 65.90% |
| Average Basic Shares Outstanding | 24.38% | 21.71% | 19.96% | 17.45% | 15.89% |
| Average Diluted Shares Outstanding | 26.01% | 23.39% | 21.71% | 19.26% | 15.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |